drugset
drugset / Trial / NCT01133574

This is a Single Ascending Dose Tolerance Study

NCT01133574 ↗

Phase 1 Terminated 47 enrolled Abbott Quintiles, Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a single rising dose tolerance (Part A) followed by a functional magnetic resonance imaging (Part B)

Timeline

Start
2010-02
Primary completion
2010-07
Completion
2010-07

Outcome

Outcome not reported

Stopped: “Part A completed successfully 22 July 2010, Part B will be separate PET study”

Drugs

EvaluationDrugModalityDoseRoute
Subject SLV354 Unknown 20 mg Oral
Subject SLV354 Unknown 60 mg Oral
Subject SLV354 Unknown 120 mg Oral
Subject SLV354 Unknown 250 mg Oral
Subject SLV354 Unknown 500 mg Oral
Subject SLV354 Unknown 750 mg Oral
Subject SLV354 Unknown 1000 mg Oral
Subject SLV354 Unknown 1250 mg Oral

Indications

cognitive disorder